Drug intelligence / Profile preview

EGTX-001

Development stage: Unknown
Lead developer: Engitix Therapeutics
Modality: Small Molecules

Overview

EGTX-001 is a chemical drug in early-stage development by Engitix Ltd. It is described as a "pan-anti fibrotic" agent, intended for the treatment of fibrosis and potentially other fibrotic diseases. The drug is being developed using Engitix’s proprietary extracellular matrix (ECM)-based discovery platform, which focuses on targeting both intracellular and extracellular drivers of fibrogenic responses. As of June 2025, EGTX-001 remains in the discovery phase with no clinical trials or regulatory approvals reported[1][2][3][4].

Other names: EGTX-001EGTX001EGTX 001

Beyond the preview

Go deeper on EGTX-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EGTX-001.

Explore the full profile